[HTML][HTML] Decreasing the Burden of Non-Alcoholic Fatty Liver Disease: from Therapeutic Targets to Drug Discovery Opportunities

R Amorim, P Soares, D Chavarria, S Benfeito… - European Journal of …, 2024 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) presents a pervasive global pandemic, affecting
approximately 25% of the world's population. This grave health issue not only demands …

Oxidative Stress as a Target for Non-Pharmacological Intervention in MAFLD: Could There Be a Role for EVOO?

A Seidita, A Cusimano, A Giuliano, M Meli, A Carroccio… - Antioxidants, 2024 - mdpi.com
Oxidative stress plays a central role in most chronic liver diseases and, in particular, in
metabolic dysfunction-associated fatty liver disease (MAFLD), the new definition of an old …

[HTML][HTML] Vitamin D Mitigates Hepatic Fat Accumulation and Inflammation and Increases SIRT1/AMPK Expression in AML-12 Hepatocytes

E Chang - Molecules, 2024 - mdpi.com
Emerging evidence has demonstrated a strong correlation between vitamin D status and
fatty liver disease. Aberrant hepatic fat infiltration contributes to oxidant overproduction …

What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?

K Ferenc, S Jarmakiewicz-Czaja, R Filip - Life, 2023 - mdpi.com
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver
disease. As the second stage of developing steatosis, nonalcoholic hepatitis (NASH) carries …

[PDF][PDF] The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis.

YJ Mi, Z Zhang, SL Jin, HM Yan… - European Review for …, 2024 - europeanreview.org
OBJECTIVE: This study delves into the role of N-terminal propeptide type III collagen
(PIIINP) in the diagnosis and management of liver pathological changes associated with non …